Minnesota is currently home to 2064 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Choline Supplementation As a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders Study
NCT05108974
Recruiting
This is a randomized, double-blind controlled trial of choline supplementation in children with Fetal Alcohol Spectrum Disorders (FASD). The study is comparing two administration durations (3 months vs. 6 months) of choline. The primary outcome measures are cognitive measures.
Gender:
ALL
Ages:
Between 30 months and 72 months
Trial Updated:
11/15/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Fetal Alcohol Spectrum Disorders
Register for Updates
Neuromodulation and Cognitive Training in Opioid Use Disorder
NCT03773523
Recruiting
The relapsing nature of opioid use disorder is a major obstacle to successful treatment. About 90% of those entering treatment will relapse within one year. To improve treatment outcome, new interventions targeting the underlying brain biomarkers of relapse vulnerability hold significant promise in reducing this critical public health problem. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that can modulate brain connectivity.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/15/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Opioid-use Disorder, Opioid Dependence, Opioid Abuse
Register for Updates
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
NCT03763643
Recruiting
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Gender:
ALL
Ages:
Between 1 year and 65 years
Trial Updated:
11/15/2024
Locations: Children's Hospital of Colorado, Aurora, Minnesota
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
The Myelin Disorders Biorepository Project
NCT03047369
Recruiting
The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago. Researchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies,... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/15/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, Aicardi Goutieres Syndrome, Metachromatic Leukodystrophy, TUBB4A-Related Leukodystrophy, 4H Syndrome, Krabbe Disease, Alexander Disease, Pelizaeus-Merzbacher Disease, Adrenoleukodystrophy, Adrenomyeloneuropathy, Multiple Sulfatase Deficiency, Megalencephalic Leukoencephalopathy With Subcortical Cysts, Vanishing White Matter Disease, Cockayne Syndrome, Labrune Syndrome, ADLD, Gangliosidoses, Peroxisomal Biogenesis Disorder, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, AGS, Alexanders Leukodystrophy, AxD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, GALC Deficiency, Globoid Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, MLD, PMD, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, GM2 Gangliosidosis, BPAN, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Register for Updates
Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)
NCT02583672
Recruiting
The purpose of this study is to measure levels of blood and brain chemicals related to oxidative stress and inflammation in healthy volunteers and individuals with Type 1 Gaucher disease (GD1) to see if these levels are altered by GD1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Gaucher Disease Type 1
Register for Updates
Myocardial Mechanisms in Heart Failure With Preserved Ejection Fraction
NCT06517186
Recruiting
The purpose of this study is to identify changes in heart tissue structure and biological function in patients with heart failure by performing an endomyocardial biopsy (EMB or heart biopsy) during a right heart catheterization (RHC). The ultimate goal is to use this information to develop new treatments for heart failure.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
11/14/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
Register for Updates
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989
Recruiting
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Refractory Differentiated Thyroid Gland Carcinoma
Register for Updates
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
NCT06413173
Recruiting
The proposed study will evaluate a new approach to cognitive rehabilitation of mTBI using a brain stimulation technique called "Remotely Supervised Transcranial Direct Current Stimulation combined with Cognitive Training" (RS-tDCS+) which has shown promise for improving complex attention in both healthy and clinical populations. RS-tDCS+ is a home-based, low-risk, non-invasive technique that is designed to boost cognitive training by enhancing learning and the brain's ability to reorganize conne... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/14/2024
Locations: Minneapolis VA Health Case System, Minneapolis, Minnesota
Conditions: Brain Concussion, Brain Trauma, Attention Concentration Difficulty, Brain Injuries, Brain Injuries, Traumatic, Neurocognitive Dysfunction, Attention Impaired, Memory Impairment, Mild Traumatic Brain Injury, Mild Cognitive Impairment, Post Concussive Symptoms
Register for Updates
Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture
NCT06278987
Recruiting
The purpose of this study is to determine if patients with hip fractures who undergo cryoablation of the PENG have improved pain control 30 days from surgery when compared to those who have a fascia iliaca catheter.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/14/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hip Fractures
Register for Updates
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
NCT06160206
Recruiting
This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy alone, works in treating patients with glioblastoma that has come back after a period of improvement (recurrent). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as retifanlimab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Register for Updates
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
NCT05910801
Recruiting
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating patients with mantle cell lymphoma that has come back (after a period of improvement) (relapsed) or that has not responded to previous treatment (refractory). Tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells. Venetocl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Register for Updates
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968
Recruiting
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0425), Minneapolis, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates